Abbott Laboratories ABT

Abbott Laboratories (ABT) closed at $101.07, down 2.34% in the session, underperforming the S&P 500’s slight decline while the Dow fell 0.31% and the Nasdaq was flat. Over the past month ABT has fallen about 9.3%, worse than the Medical-Products sector (-4.15%) and the S&P 500 (+0.53%). Ahead of its next earnings release, Abbott is expected to report EPS of $1.43, up ~10% YoY, with revenue around $12.91 billion, up ~13.5%. For the year, the consensus calls for $5.52 per share on $50.32 billion in revenue, roughly +7.18% and +13.51% YoY. The Forward P/E is 18.74, below the industry’s 20.18, and the PEG is 1.92 (vs. about 1.74 for Medical-Products). Zacks ranks ABT at #3 (Hold). Upcoming results show modest growth expectations (EPS +10% YoY; revenue +13.5%), with a Hold rating indicating a balanced near-term risk-return outlook.

Tributary Capital's Q2 2026 investor letter highlights Abbott Laboratories (ABT) as facing a slow Nutrition segment recovery and intensified competition in Structural Heart and Continuous Glucose Monitor businesses, with Electrophysiology tailwinds offsetting some headwinds. Citi views ABT as undervalued relative to its segments. As of September 23, 2026, ABT closed at $103.49, down 7.27% in the last month and 22.37% over the past 52 weeks; market cap about $179.08 billion; 52-week range $81.97–$135.45. ABT was not among the Hedge Fund 40 Most Popular Stocks list, but 86 funds held it at quarter-end (up from 73). The piece also touches AI-driven gains in the broader portfolio and positions ABT within ongoing AI and onshoring investment themes. Near-term headwinds in Nutrition and rising competition in Structural Heart and CGM imply modest downside risk to ABT's growth and valuation.

Abbott teamed with Berry Street to offer Lingo's OTC continuous glucose monitor paired with Berry Street's virtual nutrition coaching, signaling a push into consumer health and dietitian-supported care tied to Abbott's devices. Separately, the Volt Pulsed Field Ablation System completed its first procedures in Canada and at UnityPoint Health - Trinity Heart Center, underscoring potential device-led growth in atrial fibrillation care. Abbott also agreed to pay about $385 million to settle infant formula quality and safety allegations, highlighting ongoing legal/regulatory exposure in Nutrition. The narrative suggests digital health offerings and device adoption could lift Abbott's Devices-led investment case, even as Nutrition litigation risks linger. Abbott's forecast envisions about $60 billion in revenue and $9.6 billion in earnings by 2029, with fair-value estimates pointing to upside but tempered by settlements and regulatory headwinds. Volt deployments and Lingo partnership could strengthen Abbott's devices growth trajectory, while the $385 million infant formula settlement introduces near-term regulatory and margin risk.

Focus Wealth Management's Q2 2026 investor letter highlights a broad market rally driven by resilient earnings, AI investment, and semiconductor strength, while warning of excessive optimism and rich valuations tied to ambitious AI growth assumptions. The letter depicts a 'tale of two realities' where AI-related capex thrives even as overall growth remains subdued, and questions whether hyperscaler investments will deliver returns to justify current valuations. It notes rising capital needs and potential AI-spending slowdowns as key risks, urging caution amid market complacency. Within this context, Focus initiated a position in Abbott Laboratories (ABT), praising its diversified healthcare franchises, dividend growth record (over 50 years), ongoing innovation, resilience, and what they view as temporarily contending operational challenges. ABT stock data: Sep 22, 2026 close at $103.69; 1-month -9.12%; 52-week range $81.97–$136.83; market cap ~$179.4B. Initiating a position amid temporary operational headwinds suggests a moderate uplift in ABT's near-term trajectory rather than a fundamental shift.

Abbott Laboratories (ABT) has become a trending stock in Zacks' coverage, with investors watching earnings revisions and growth outlook. Over the past month, ABT shares fell about 10.7%, underperforming the S&P 500 (+1.3%), and the Zacks Medical – Products industry (-7.7%). Key drivers are revisions to near-term and long-term earnings estimates: current quarter EPS expected at $1.43, up 10% year over year, with the consensus up 0.2% over the last 30 days. For the current year, consensus EPS is $5.52 (+7.2%), and for next year $6.08 (+10.2%), both unchanged recently. Revenues are projected at $12.91B this quarter (+13.5%), $50.32B this year (+13.5%), and $54.51B next year (+8.3%). Abbott beat revenue and EPS estimates in the last reported quarter, with revenue of $12.59B (+13%) and EPS of $1.31. Valuation is fair relative to peers (Value Score C), and Zacks ranks ABT #2 (Buy), suggesting potential near-term outperformance. Earnings revisions and a Buy rating imply modest near-term upside, not a transformative catalyst.

Abbott (ABT) and Berry Street have formed an exclusive partnership to fuse Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered nutrition coaching, enabling users to translate real-time glucose data into personalized dietary actions. Lingo, an OTC CGM for adults not on insulin, provides glucose insights showing how food, activity, sleep, and stress impact metabolism. Berry Street will offer registered dietitian guidance trained on Lingo, via virtual one-on-one sessions and a tailored nutrition plan, with in-network coverage from over 1,250 health plans and 96% no out-of-pocket costs. Berry Street users can get Lingo at a discounted price (4-week plans) and Lingo data can be shared with dietitians for enhanced coaching. Researchers note RD-led nutrition therapy improves glucose control and cardiometabolic markers, underscoring the potential benefits of combining data and expert support. Expands consumer health reach and personalized nutrition capabilities, likely modest near-term revenue impact.

Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) show divergent revenue trajectories. Abbott, with a broad portfolio of devices, diagnostics, nutrition, and generics, posted about 14% operating margin for the quarter ended June 30, 2026, and is expanding through a licensing deal with ALZpath while resolving infant-formula litigation claims. Intuitive, maker of robotic systems, faced recalls and softer domestic procedure volumes but carried a 34% operating margin and launched a patient-awareness campaign. Revenue trends through Q3 2024–Q2 2026 show Abbott at roughly $10.6–12.6B across quarters, while Intuitive rose from about $2.0B to $2.9B. Over this period, Intuitive’s revenue grew about 45%, ahead of Abbott’s roughly 19% growth, but Abbott still held a roughly $10B revenue lead. Both benefit from recurring revenue; Abbott pays a 2.5% dividend, Intuitive does not. Shares have both declined recently. Foolish Stock Advisor identified other top picks. Incremental licensing and litigation settlements offer modest tailwinds for Abbott, with no transformative catalysts evident.

J&J sells Laminar LAA closure assets it bought 3 years ago. J&J exit from LAA closure reduces competition for Abbott in that market segment.

Abbott Laboratories agrees to $385 million settlement over infant formula recall. The settlement creates a large one-time financial hit to Abbott's core infant formula operations without shifting long-term strategy.

Abbott Laboratories faces a $384 million cost from ongoing legal risks tied to infant formula. Legal costs and persistent risks in infant formula may moderately affect financials without altering overall trajectory.

Abbott's Volt Pulsed Field Ablation System achieves first commercial use in Canada for atrial fibrillation treatment. Initial Canadian commercial rollout of Volt PFA system expands Abbott's atrial fibrillation ablation presence.

Abbott Laboratories agrees to settlement over closure of largest baby formula plant in the US. Settlement over major plant closure signals ongoing supply constraints and operational adjustments for core formula business.

Abbott Laboratories received FDA approval for TactiFlex Duo, a development expected to support potential stock gains. FDA approval of TactiFlex Duo constitutes a major product milestone that can strengthen Abbott's electrophysiology offerings and revenue outlook.

Abbott Laboratories secured FDA approval for its dual ablation catheter. FDA clearance for the dual ablation catheter supports Abbott's electrophysiology product line and potential revenue growth in cardiac procedures.

The first FDA-cleared Alzheimer's blood test has redefined competition in the blood-based biomarkers market, with a new report highlighting resulting shifts for companies including Abbott Laboratories. FDA clearance of the Alzheimer's blood test creates major new positioning for Abbott in diagnostics and market dynamics.

Abbott Laboratories secured FDA approval for its TactiFlex Duo Ablation Catheter to treat abnormal heart rhythms. FDA approval of TactiFlex Duo Ablation Catheter enables expanded electrophysiology product sales and market share gains.

Abbott introduces America’s first liquid baby formula with whole milk. New whole-milk liquid formula launch expands Abbott infant nutrition offerings with moderate competitive positioning upside.

Abbott Laboratories launches new infant formula, signaling strategic moves in its nutrition business to investors. New infant formula launch indicates moderate effects on Abbott's product innovation and competitive positioning.

Abbott Laboratories aligns strategies with RFK Jr.'s Make America Healthy Again movement to support public health goals and adjust product focus. Alignment with shifting health policies may moderately reshape Abbott's nutritional offerings and regulatory positioning.

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula. New product adds differentiation in infant nutrition without shifting overall company trajectory.

Abbott Laboratories secured CE mark approval for its new left atrial appendage closure device, enabling commercialization across Europe. CE mark opens European sales channel for new cardiovascular device, supporting moderate revenue growth.

FDA approves Abbott's first wearable device for dual ketone and glucose tracking. FDA approval launches innovative dual-tracking wearable that expands Abbott's core diabetes monitoring portfolio and market reach.

FDA grants Abbott first approval for a diabetes product. Stock has declined but may rebound on the regulatory win. First-in-kind FDA approval in core diabetes business strengthens competitive position and supports future growth.

Dexcom and Abbott Laboratories await Medicare coverage expansion for continuous glucose monitors. Medicare coverage expansion for CGMs would boost Abbott's sales and market access for its diabetes monitoring products.

Abbott Laboratories received CE Mark approval for its next-generation Amulet 360 device to treat atrial fibrillation patients at risk of stroke. CE Mark for Amulet 360 supports European commercialization of Abbott's atrial fibrillation device and may lift related device sales.

Abbott Laboratories secured FDA clearance for a diabetes device, advancing its push into diabetes care technology and market expansion. FDA clearance enables faster commercialization of Abbott diabetes devices and strengthens its position against competitors.

FDA approves Abbott's first wearable device for simultaneous ketone and glucose tracking. FDA clearance of novel dual-monitoring wearable expands Abbott's diabetes technology offerings and strengthens its market position.

Abbott Laboratories received FDA authorization for the world's first dual glucose-ketone sensing technology for people with diabetes. FDA approval of first-in-class dual glucose-ketone sensor expands Abbott's diabetes portfolio and competitive edge.

Abbott Laboratories pays $670 million to settle formula claims as legal risks persist. Large settlement payout resolves certain claims but ongoing legal exposure may weigh on finances and investor views.

Abbott Laboratories diagnostics growth is driven by market trends, product innovations and competitive dynamics in healthcare testing. Diagnostics growth factors moderately influence Abbott's revenue trajectory and competitive stance.